Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 18 people in total — 9 in a group using an active PEMF (pulsed electromagnetic field) device, and 9 using a placebo (inactive) version of the same device. PEMF is a type of therapy that uses electromagnetic pulses applied to the body. The trial was looking at whether using the active device alongside standard treatment made any difference to eye inflammation in people with a condition called anterior uveitis, which is swelling and irritation inside the front part of the eye. All 9 participants in the active device group finished the trial, while 8 of the 9 in the placebo group completed it. The reported data shows one primary outcome measure: the level of eye inflammation at day 7, scored on a scale from 0 to 4, where 0 means minimal inflammation and 4 means the most severe level. According to the results reported on ClinicalTrials.gov, the active device group had an average score of 0.625 at day 7, while the placebo device group had an average score of 1.444 at day 7. No other outcome measures were included in the submitted results data, so additional findings beyond this inflammation score were not reported. It is worth noting that this was a very small trial — fewer than 10 people in each group — and only one set of numbers was submitted. The reported data shows only what was measured and recorded in this particular study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 3589667) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed by a doctor with anterior uveitis (also called iritis), which is inflammation at the front of the eye
- Your uveitis is not caused by an infection
- You are generally in good health apart from this eye condition
- You are 18 years of age or older
- An eye doctor (ophthalmologist) running the study has confirmed you are suitable to take part
Who may not be able to join:
- Anyone under 18 years of age
- Women who are pregnant
- People who are in prison
- Anyone who is not able to read, understand, and sign a written consent form due to a mental or physical condition
- People who have a pacemaker fitted, as the study uses electromagnetic fields that could interfere with it
- People who have any metal implants made of ferromagnetic material (a type of metal that can be affected by magnetic or electromagnetic fields) — (confirm with trial site if you are unsure whether your implant qualifies)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Inflammation Grade at Day 7
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.